Promoter polymorphisms and allelic imbalance in ABCB1 expression

Pharmacogenetics and Genomics

Volumn 17, Issue 11, 2007, Pages 951-959

  Loeuillet, Corinne ^a   Weale, Michael ^c   Deutsch, Samuel ^b   Rotger, Margalida ^a   Soranzo, Nicole ^d   Wyniger, Josiane ^a   Lettre, Guillaume ^d   Dupré, Yann ^b   Thuillard, Delphine ^a   Beckmann, Jacques S ^a   Antonarakis, Stylianos E ^b   Goldstein, David B ^c   Telenti, Amalio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allelic imbalance; Centre d'Etude du Polymorphisme Humain; MDR1; P glycoprotein; Pyrosequencing

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ABCB1 GENE; ALLELE; ARTICLE; B LYMPHOCYTE; CIS ISOMER; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HETEROZYGOSITY; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MULTIGENE FAMILY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELIC IMBALANCE; B-LYMPHOCYTES; CELLS, CULTURED; COHORT STUDIES; FAMILY; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; HUMANS; MALE; NELFINAVIR; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RNA, MESSENGER;

EID: 37349041369     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282eff934     Document Type: Article

References (34)

1. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
2. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
3. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
4. Kim RB. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12:425-427.
5. Ishikawa T, Tsuji A, Inui K, Sai Y, Anzai N, Wada M, et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 2004; 5:67-99.
6. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la CM, et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A 2003; 100:5896-5901.
7. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-494.
8. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
9. Bleiber G, May M, Suarez C, Martinez R, Marzolini C, Egger M, et al. MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. J Infect Dis 2004; 189:583-586.
10. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the intracellular concentration of nelfinavir. Pharmacogenetics Genomics 2005; 15:599-608.
11. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 2004; 14:1333-1344.
12. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulation of the human MDR1 gene at the level of the inverted MED-1 promoter region. Ann N Y Acad Sci 2002; 973:468-471.
13. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 2002; 64:943-948.
14. Cann HM, de Toma C, Cazes L, Legrand MF, Morel V, Piouffre L, et al. A human genome diversity cell line panel. Science 2002; 296:261-262.
15. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, White R. Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics 1990; 6:575-577.
16. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005; 437:1299-1320.
17. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289-294.
18. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-3601.
19. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
20. Wittkopp PJ, Haerum BK, Clark AG. Evolutionary changes in cis and trans gene regulation. Nature 2004; 430:85-88.
21. Deutsch S, Rideau A, Bochaton-Piallat ML, Merla G, Geinoz A, Gabbiani G, et al. Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome. Blood 2003; 102:529-534.
22. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin: rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002; 30:97-101.
23. Wang B, Ngoi S, Wang J, Chong SS, Lee CG. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines. Mol Pharmacol 2006; 70:267-276.
24. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. Allelic variation in human gene expression. Science 2002; 297:1143.
25. Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003; 13:1855-1862.
26. Bray NJ, Buckland PR, Owen MJ, O'Donovan MC. Cis-acting variation in the expression of a high proportion of genes in human brain. Hum Genet 2003; 113:149-153.
27. Heighway J, Bowers NL, Smith S, Betticher DC, Koref MF. The use of allelic expression differences to ascertain functional polymorphisms acting in cis: analysis of MMP1 transcripts in normal lung tissue. Ann Hum Genet 2005; 69:127-133.
28. Liljedahl U, Fredriksson M, Dahlgren A, Syvanen AC. Detecting imbalanced expression of SNP alleles by minisequencing on microarrays. BMC Biotechnol 2004; 4:24.
29. Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, Lepage P, et al. A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics 2004; 16:184-193.
30. Pastinen T, Ge B, Hudson TJ. Influence of human genome polymorphism on gene expression. Hum Mol Genet 2006; 15(Spec No 1):R9-R16.
31. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 2005; 15:693-704.
32. Randle RA, Raguz S, Higgins CF, Yague E. Role of the highly structured 5-end region of MDR1 mRNA on P-glycoprotein expression. Biochem J 2007; Jun 15 [Epub ahead of print].
33. Srinivas RV, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42:3157-3162.
34. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528.